Tumor Biology

, Volume 37, Issue 5, pp 6261–6265 | Cite as

RETRACTED ARTICLE: Expression and prognostic value of the aldehyde dehydrogenase 1 (ALDH1) and N-myc downstream regulated gene 2 (NDRG2) as potential markers in human astrocytomas

  • Peyman Karimi Goudarzi
  • Farzad Mehrabi
  • Reza Jalili Khoshnood
  • Ali Baradaran Bagheri
  • Koorosh Ahmadi
  • Emad Yahaghi
  • Hesam Abdolhoseinpour
Original Article

Abstract

In this study, immunohistochemical analysis was used to evaluate the expression of ALDH1 and NDRG2 in astrocytoma tissue samples and normal brain tissues. ALDH1 protein staining displayed that AlDH1 expression was not detectable in eight astrocytoma tissues (8/36) and in all of normal brain tissues. There was a significant difference between ALDH1 expression and WHO grades (P = 0.03). Furthermore, no correlation was determined between expression levels of ALDH1 and other clinicopathological characteristics including age, sex, and tumor size. Immunohistochemistry showed that a high level of NDRG2 protein expression was markedly detected in normal brain tissues and expression of NDRG2 protein was significantly decreased in astrocytoma tissues. There was a significant association between pathological grading and NDRG2 expression level (P < 0.001, Table 1), but no correlation was determined between expression levels of NDRG2 and other clinicopathological characteristics including age, sex, and tumor size. We also obtained detailed follow-up data and evaluated the association of ALDH1/NDRG2 expressions with overall survival. Kaplan–Meier survival and log-rank analysis indicated that the patients with high proportion of ALDH1-positive cells and low proportion of NDRG2-positive had shorter overall survival (P < 0.001; P = 0.001). Univariate analysis indicated that the high proportion of ALDH1-positive cells (P < 0.001), the low proportion of NDRG2-positive cells (P = 0.009), and the advanced grade (P < 0.005) were markedly linked to the prognosis in patients. Furthermore, in the multivariate analysis, ALDH1 cells’ expression (P = 0.012), low proportion of NDRG2-positive cells (P = 0.025), and advanced grade (P < 0.03) were linked to poor overall survival. Our results suggest that NDRG2 expression is related to decreased survival rates and NDRG2 may be a potential marker in the astrocytoma prognosis. NDRG2 may be a potential marker in the astrocytoma prognosis. ALDH1 expression was related to advanced pathological grade and survival rate in astrocytoma patients.

Keywords

Astrocytoma NDRG2 ALDH1 Prognostic Immunohistochemistry 

Notes

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Malkoun N, Chargari C, Forest F, Fotso MJ, Cartier L. Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol. 2012;106:127–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Natsume A, Kato T, Kinjo S, Enomoto A, Toda H. Girdin maintains the stemness of glioblastoma stem cells. Oncogene. 2012;31:2715–24.CrossRefPubMedGoogle Scholar
  4. 4.
    Wang Y, Li S, Chen L, You G, Bao Z. Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol. 2012;14:518–25.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Carico C, Nuno M, Mukherjee D, Elramsisy A, Dantis J. Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS One. 2012;7:e33684.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Norden AD, Wen PY. Glioma therapy in adults. Neurologist. 2006;12:279–92.CrossRefPubMedGoogle Scholar
  7. 7.
    Stylli SS, Kaye AH, MacGregor L. Photodynamic therapy of high grade glioma—long term survival. J Clin Neurosci. 2005;12:389–98.CrossRefPubMedGoogle Scholar
  8. 8.
    Chu SH, Ma YB, Feng DF. Correlation of low SLC22A18 expression with poor prognosis in patients with glioma. J Clin Neurosci. 2012;19:95–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Chu SH, Feng DF, Ma YB. Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. J Transl Med. 2011;9:156.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Vasiliou V, Pappa A, Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact. 2000;129:1–19.CrossRefPubMedGoogle Scholar
  11. 11.
    Patel M, Lu L, Zander DS. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors. Lung Cancer. 2008;59:340–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Jiang F, Qiu Q, Khanna A. Aldehyde dehydrogenase 1 is a tumor stem cell associated marker in lung cancer. Mol Cancer Res. 2009;7:330–8.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Croker AK, Goodale D, Chu J. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009;13:2236–52.CrossRefPubMedGoogle Scholar
  14. 14.
    Su Y, Qiu Q, Zhang X. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:327–37.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ginestier C, Hur MH, Charafe-Jauffret E, Monvile F, Dutcher J. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67:2187–96.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Balicki D. Moving forward in human mammary stem cell biology and breast cancer prognostication using ALDH1. Cell Stem Cell. 2007;1(5):485–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Moreb JS. Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther. 2008;3(4):237–46.CrossRefPubMedGoogle Scholar
  19. 19.
    Hu XL, Liu XP, Lin SX, Deng YC, Liu N, Li X. NDRG2 expression and mutation in human liver and pancreatic cancers. World J Gastroenterol. 2004;10:3518–21.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hummerich L, Muller R, Hess J, Kokocinski F, Hahn M, Furstenberger G, et al. Identification of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development. Oncogene. 2006;25:111–21.PubMedGoogle Scholar
  21. 21.
    Lorentzen A, Vogel LK, Lewinsky RH, Saebo M, Skjelbred CF, Godiksen S, et al. Expression of NDRG2 is down-regulated in high-risk adenomas and colorectal carcinoma. BMC Cancer. 2007;7:192.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X. N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer. 2003;106:342–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Huang EH, Hynes MJ, Zhang T. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009;69:3382–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Awad O, Yustein JT, Shah P. High ALDH activity identifies chemotherapy resistant Ewing’s sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition. PLoS One. 2010;5:e13943.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Clay MR, Tabor M, Owen JH. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010;32:1195–201.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010;16(1):45–55.CrossRefPubMedGoogle Scholar
  27. 27.
    Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009;385:307–13.CrossRefPubMedGoogle Scholar
  28. 28.
    Liu DY, Ren CP, Yuan XR, Zhang LH, Liu J, Liu Q. ALDH1 expression is correlated with pathologic grade and poor clinical outcome in patients with astrocytoma. J Clin Neurosci. 2012;19(12):1700–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Tanei T, Morimoto K, Shimazu K. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009;15:4234–41.CrossRefPubMedGoogle Scholar
  30. 30.
    Choi SC, Yoon SR, Park YP, Song EY, Kim JW, Kim WH. Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med. 2007;39:705–14.CrossRefPubMedGoogle Scholar
  31. 31.
    Li L, Wang J, Shen X, Wang L, Li X, Liu Y. Expression and prognostic value of NDRG2 in human astrocytomas. J Neurol Sci. 2011;308(1–2):77–82.CrossRefPubMedGoogle Scholar
  32. 32.
    Kogiku M, Ohsawa I, Matsumoto K, Sugisaki Y, Takahashi H, Teramoto A. Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. J Clin Neurosci. 2008;15:1198–203.CrossRefPubMedGoogle Scholar
  33. 33.
    Sun B, Chu D, Li W, Chu X, Li Y, Wei D. Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J Neurooncol. 2009;94:213–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Schilling SH, Hjelmeland AB, Radiloff DR, Liu IM, Wakeman TP, Fielhauer JR. NDRG4 is required for cell cycle progression and survival in glioblastoma cells. J Biol Chem. 2009;284:25160–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Tepel M, Roerig P, Wolter M, Gutmann DH, Perry A, Reifenberger G. Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer. 2008;123:2080–6.CrossRefPubMedGoogle Scholar
  36. 36.
    Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18:3004–16.CrossRefPubMedGoogle Scholar
  37. 37.
    Zhao H, Zhang J, Lu J, He X, Chen C, Li X. Reduced expression of N-Myc downstream-regulated gene 2 in human thyroid cancer. BMC Cancer. 2008;8:303.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Shi H, Jin H, Chu D, Wang W, Zhang J, Chen C. Suppression of N-myc downstream-regulated gene 2 is associated with induction of Myc in colorectal cancer and correlates closely with differentiation. Biol Pharm Bull. 2009;32:968–75.CrossRefPubMedGoogle Scholar
  39. 39.
    Lorentzen A, Lewinsky RH, Bornholdt J, Vogel LK, Mitchelmore C. Expression profile of the N-myc downstream regulated gene 2 (NDRG2) in human cancers with focus on breast cancer. BMC Cancer. 2011;11:14.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Peyman Karimi Goudarzi
    • 1
  • Farzad Mehrabi
    • 2
  • Reza Jalili Khoshnood
    • 3
  • Ali Baradaran Bagheri
    • 4
  • Koorosh Ahmadi
    • 5
  • Emad Yahaghi
    • 6
  • Hesam Abdolhoseinpour
    • 7
  1. 1.Department of NeurosurgeryAJA University of Medical SciencesTehranIran
  2. 2.Department of NeurologyAJA University of Medical SciencesTehranIran
  3. 3.Department of NeurosurgeryShahid Beheshti University of Medical SciencesTehranIran
  4. 4.Department of NeurosurgeryAlborz University of Medical SciencesKarajIran
  5. 5.Department of Emergency MedicineAlborz University of Medical SciencesKarajIran
  6. 6.Department of Molecular BiologyBaqiyatallah University of Medical SciencesTehranIran
  7. 7.Department of Neurosurgery, Bou Ali Hospital, Tehran Medical Sciences BranchIslamic Azad UniversityTehranIran

Personalised recommendations